|
J Biol Chem, Vol. 275, Issue 16, 12237-12242, April 21, 2000
Functional Properties of a New Voltage-dependent
Calcium Channel 2 Auxiliary Subunit Gene
(CACNA2D2) *
Boning
Gao ,
Yoshitaka
Sekido ,
Anton
Maximov§,
Mohamad
Saad ,
Eva
Forgacs ,
Farida
Latif¶,
Ming H.
Wei ,
Michael
Lerman ,
Jung-Ha
Lee**,
Edward
Perez-Reyes**,
Ilya
Bezprozvanny§, and
John D.
Minna 
From the Hamon Center for Therapeutic Oncology
Research, Departments of Internal Medicine, Pharmacology, and
§ Physiology, University of Texas, Southwestern Medical
Center, Dallas, Texas 75390, ¶ University of Birmingham,
Birmingham B15 2TT, United Kingdom, Laboratory of Immunobiology,
NCI-Frederick Cancer Research and Development Center, Frederick,
Maryland 21702, and ** Department of Pharmacology, University of
Virginia, Charlottesville, Virginia 22908
 |
ABSTRACT |
We have positionally cloned and characterized a
new calcium channel auxiliary subunit, 2 -2
(CACNA2D2), which shares 56% amino acid identity with the
known 2 -1 subunit. The gene maps to the critical
human tumor suppressor gene region in chromosome 3p21.3, showing very
frequent allele loss and occasional homozygous deletions in lung,
breast, and other cancers. The tissue distribution of
2 -2 expression is different from
2 -1, and 2 -2 mRNA is most
abundantly expressed in lung and testis and well expressed in brain,
heart, and pancreas. In contrast, 2 -1 is expressed predominantly in brain, heart, and skeletal muscle. When co-expressed (via cRNA injections) with 1B and 3
subunits in Xenopus oocytes, 2 -2
increased peak size of the N-type Ca2+ currents 9-fold, and
when co-expressed with 1C or 1G subunits in Xenopus oocytes increased peak size of L-type channels
2-fold and T-type channels 1.8-fold, respectively. Anti-peptide
antibodies detect the expression of a 129-kDa 2 -2
polypeptide in some but not all lung tumor cells. We conclude that the
2 -2 gene encodes a functional auxiliary subunit of
voltage-gated Ca2+ channels. Because of its chromosomal
location and expression patterns, CACNA2D2 needs to be
explored as a potential tumor suppressor gene linking Ca2+
signaling and lung, breast, and other cancer pathogenesis. The homologous location on mouse chromosome 9 is also the site of the mouse
neurologic mutant ducky (du), and thus,
CACNA2D2 is also a candidate gene for this inherited
idiopathic generalized epilepsy syndrome.
 |
INTRODUCTION |
Electrophysiological and molecular cloning studies have revealed
an incredible diversity of voltage-gated calcium channels. They are
formed by heteromultimeric complexes of 1, 2 , ,
and subunits. The 1 subunits contain the channel pore, voltage sensors, and the receptors for various classes of drugs and toxins (1).
There are three families of 1 subunits: the L-type,
Cav1, family, composed of 1S, 1C
(Cav1.2), 1D, and 1F; the non-L-type high
voltage-activated, or Cav2, family, which contains the
P/Q-types encoded by 1A, the N-type encoded by 1B
(Cav2.2), and R-types encoded by 1E; and the T-type
family, or Cav3, encoded by 1G (Cav3.1),
1H, and 1I (2). The subunit family is less diverse, with only
four genes cloned so far (3). Co-expression studies have established
two physiological roles of subunits in high voltage-activated
Ca2+ channels: they dramatically increase 1 expression
at the plasma membrane, and they alter the biophysical properties of
the channel currents. In general, subunits have little effect on
the expression of low voltage-activated currents (4). Although only one
and 2 subunit have been characterized
biochemically, recent evidence suggests that there may be additional
members of these gene families (5-7). The 1 subunit was shown to be
part of the skeletal muscle L-type channel (8); coexpression studies
have indicated that it aids in the formation of L-type channels, as assayed by dihydropyridine binding (9), and may play a role in channel
inactivation (10).
The 2 subunit ( 2 -1) was first
identified in biochemical studies of skeletal muscle L-type
Ca2+ channels (reviewed in Ref. 1). Using antibodies, it
has also been shown to be part of the cardiac L-type and neuronal
N-type channels (11, 12). 2 -1 cDNA has been
cloned from skeletal muscle and brain cDNA libraries (13-15). The
175-kDa protein product is post-translationally cleaved to form
disulfide-linked 2 and peptides, both of which are
heavily glycosylated. Biochemical and mutation analysis supports a
single transmembrane domain in the subunit that anchors the
2 protein to the membrane (16). Coexpression of
2 -1 with both high voltage-activated and low voltage-activated 1 subunits facilitates the assembly of channels in
the plasma membrane (4, 9, 17). Coexpression studies also indicate that
2 -1 can alter the pharmacological properties of
L-type channels (18). In contrast to the subunits that have a
dramatic effect on gating of all high voltage-activated channel in many
expression systems, the effects of 2 -1 are more controversial, perhaps depending on the 1 subunit used or the expression system. For example, 2 -1 has little or no
effect on either L-type (18, 19) or N-type currents expressed in Xenopus oocytes (17) but appears to affect inactivation of
L-type channels expressed in mammalian cells (20, 21). The opposite result occurred in studies on 1E-mediated currents, where no effect
was observed in mammalian cells (22) and effects on channel inactivation were observed in Xenopus oocytes (23). The
2 -1 subunit has a high affinity binding site for the
anti-epileptic drug gabapentin (16). Gabapentin has been shown to
modestly inhibit (~30%) neuronal Ca2+ currents, although
it is unclear if this is its mechanism of action (24).
We have been attempting to identify a new human tumor suppressor gene
in chromosome region 3p21.3, where frequent allele loss and occasional
homozygous deletions have been found in lung, breast, and other human
tumors (25). Several genes in the region have been identified using
positional cloning strategies. The sequence of one of the genes and its
mRNA splicing variants in the region ( 2 -2;
GenBankTM numbers AF040709, AF042792, and AF042793; CACNA2D2) showed extensive homology with the known calcium
channel 2 -1 subunit. We have studied the tissue
distribution of expression of this new 2 -2 gene and
tested the function of the gene product in Xenopus oocytes
by coexpressing 2 -2 cRNAs along with a representative member of the three families of calcium subunit 1 subunits. We find
a pattern of expression different from the other 2
subunit, whereas the 2 -2 enhances the activity of the
calcium subunit 1 subunits.
 |
EXPERIMENTAL PROCEDURES |
Positional Cloning of 2 -2 cDNA--
A
contig1 of 22 cosmids
covering 600 kb localized to the 3p21.3 small cell lung cancer
homozygous deletions isolated from a human placental cosmid library
have been described previously (25). The entire contig was sequenced by
the joint effort of the Sanger Center (UK) and the Washington
University Genome Sequence Center. The obtained sequence information
was analyzed by BLAST and GENSCAN Informatics as well as the integrated
informatic software package developed by the Garner lab at UT
Southwestern, PANORAMA, and we found that cosmid LUCA#11 harbored an
EST clone N53512 (Genome Systems) containing a portion of the 3' end as
well as putative exons of what would be 2 -2. Further Southern
blot analysis showed that various exons of the 2 -2
gene are located on cosmid LUCA06 (GenBankTM number Z84493), LUCA07
(GenBankTM number Z84494), LUCA08 (GenBankTM number Z84495), LUCA09
(GenBankTM number Z75743) LUCA10 (GenBankTM number Z75742), and LUCA11
(GenBankTM number Z84492). Based on GENSCAN predictions, a primer set
of LUCA11pr5, 5'-CTGAGAGTGAGGATGTGGAA-3'(sense primer), and LUCA11pr18,
5'-GTGCATCCTCATACACGTTG-3' (antisense primer), was used for reverse
transcriptase-polymerase chain reaction amplification for normal lung
cDNA template, and a 960-base pair product was successfully
amplified. The 1.5-kb NotI/HindIII fragment of
the EST clone N53512 and the 960-base pair product were used as probes
on human multiple tissue Northern blots (CLONTECH).
The screening of a million clones from a lung cDNA library
(CLONTECH) with the 960-base pair reverse
transcriptase-polymerase chain reaction product yielded 120 positive
clones, which were also screened by probing clone N53512 to obtain the
clones with long inserts. Five clones randomly selected as single
positives for the 960-base pair probe and 5 clones selected as double
positive for both probes were subcloned and sequenced. All of the 10 clones had the sequence of 2 -2, suggesting that all
of the 120 clones were 2 -2. Two clones (pY720c21 and
pY724c95) that covered the longest sequence were assembled and further
inserted into a plasmid expression vector pcDNA3.1 (Invitrogen) by
standard methods.
Northern Blot Analysis--
Human multiple tissue Northern blots
(CLONTECH) were hybridized and washed according to
the manufacturer's recommendation. The three short probes were
generated using polymerase chain reaction. All probes were labeled with
a random-oligonucleotide priming kit (Rad Prime DNA labeling System,
Life Technologies, Inc.).
In Vitro Translation and Transient Transfection
Studies--
2 -2 cDNA inserted into plasmid
pcDNA3.1 (Invitrogen) was used for in vitro translation
using [35S]methionine in an in vitro
transcription/translation system (TNT Coupled Reticulocyte Systems,
Promega). For transfection experiments, non-small cell lung cancer
NCI-H1299 cells (3 × 105) were seeded in 3.5-cm
culture dishes for 24 h in RPMI 1640 containing 5% fetal bovine
serum, and then 1 µg of cloned DNA was introduced into the cells
using the LipofectAMINE reagent (Life Technologies, Inc.). For protein
expression after transfection, cells were harvested 48 h later and
were lysed in 80 µl of sample buffer (50 mM Tris, pH 6.8, 1% SDS, 10% glycerol, and 0.3M of -mercaptoethanol). NCI-H1299
cells were used for these studies because they do not express
endogenous 2 -2 mRNA or protein (see
"Results") and are homozygous for multiple polymorphic markers in
the 600-kb homozygous deletion region (26) and, thus, have undergone
loss of heterozygosity for this region.
Antibodies and Western Blots--
Peptide A
(YYDAKADAELDDPESEDVERG), corresponding to amino acids 161-181 of
2 -2 (GenBankTM number AF040709), was synthesized, and
rabbit polyclonal antibodies were raised using a commercial source
(Alpha Diagnostic, San Antonio, TX). Antibodies were affinity-purified using this peptide conjugated to agarose beads (amino link
immobilization kit; Pierce). Horseradish peroxidase-labeled anti-rabbit
antibody and chemiluminescent substrates were used to detect the
positive signal.
Electrophysiologic Studies--
For the study of coexpression
with 1B and 3 subunits, complementary RNA (cRNA) encoding human
brain 1B (27), rabbit skeletal muscle 2 -1(28),
rabbit 3 (29), and 2 -2 subunits was
synthesized in vitro using T7 RNA polymerase, resuspended in
water at a final concentration of ~1 mg/ml, and stored at 80 °C
until injection. Xenopus oocytes harvested by standard
methods (30) were injected with a mixtures of the following
transcripts: 1B+ 3,
1B+ 3+ 2 -1, 1B+ 3+ 2 -2, or 2 -2
alone (approximately 50 ng of total cRNA/oocyte). Two days later
oocytes were analyzed using standard two-electrode voltage-clamp
technique with 5 mM Ba2+ as a charge carrier
(31). The holding potential was 120 mV. Currents were recorded in
response to test potentials ranging from 110 to +100 mV, filtered at
200 Hz, then analyzed using pClamp 6.04 (Axon Instruments) and Origin
(Microcal) software. Leak and capacitance currents were subtracted
on-line with a P/4 protocol.
For the studies of coexpression with 1C and 1G subunits, cRNA of
either 1C, 1G, or 2 -2 cDNA was synthesized
using Ambion Megascript kit according to the supplier's protocol
(Ambion, Austin, TX). Due to low expression of wild-type 1C, we used
the modified cDNA N60, which is truncated by 60 amino acids at
the N-terminal end of the rabbit cardiac 1 subunit (32). The rat
brain 1G cDNA (33) was contained in the vector pGEM-HE (34).
Fifty nl of cRNA (5 ng for 1C, 5 ng for 1G, and 2.5 ng for
2 -2) of either 1C alone, 1C plus
2 -2, 1G alone, or 1G plus 2 -2 were injected into each oocyte using a Drummond Nanoject pipette injector (Parkway, PA). Expression of injected cRNA was measured from
the 4th day after injection for 1C alone or 1C plus
2 -2 and the 6-7th day after injection for 1G
alone or 1G plus 2 -2 using the two-electrode
voltage clamp method. Currents were measured in either 40 mM Ba2+ solution (40 mM
Ba(OH)2, 50 mM NaOH, 1 mM KOH, and
5 mM HEPES, adjusted to pH 7.4 with methanesulfonic acid)
for L-type currents or 10 mM Ba2+ solution (10 mM Ba(OH)2, 80 mM NaOH, 1 mM KOH, and 5 mM HEPES, adjusted to pH 7.4 with
methanesulfonic acid) for T-type currents. Data were sampled at either
2 kHz for L-type currents or 5 kHz for T-type currents using the pClamp
6 system via a Digidata 1200 A/D converter (Axon Instrument, Foster
city, CA). Leak currents were subtracted using a P/+4 for L-type
currents or a P/ 6 for T-type currents.
 |
RESULTS |
Characteristics of 2 -2 cDNA and Its Predicted
Amino Acid Sequence--
Human chromosome 3p21.3 is deleted in many
small cell lung cancers. While searching for a putative tumor
suppressor gene in this region, we identified a gene (GenBankTM number
AF040709, AF042792, and AF042793) that appeared to encode a homolog of
the 2 subunit of Ca2+ channels. An open
reading frame of 3,435 nucleotides encoding 1,145 amino acids was
identified. The molecular mass of the deduced amino acid sequence is
129,343 Da. BLAST searches and homology alignment revealed that the
predicted protein shares 56% amino acid sequence identity with the
human auxiliary 2 -1 subunit (GenBankTM number M76559)
of voltage-gated Ca2+ channels (13). Therefore we refer to
the gene product as 2 -2 and the gene as
CACNA2D2. Notably, 17 out of 22 cysteines in
2 -2 are conserved with 2 -1,
suggesting that the two proteins share similar overall secondary
structure. Similar to the 2 -1 subunit, the
2 -2 sequence contains multiple putative
N'-glycosylation sites and is likely to be glycosylated.
Tissue Specificity of 2 -2 Expression--
Tissue
distribution of 2 -2 expression was examined by
Northern blot hybridization of the human multiple tissue blots
(CLONTECH) using the entire coding region (Fig.
1, A and B) as well
as three different short probes (nucleotides 510-653 (Fig.
1C) and nucleotides 993-1152 (Fig. 1D) and
2729-3293 (Fig. 1E). An approximately 5.5-kb 2 -2 mRNA was found and appeared most abundant in
lung and testis, abundant in brain, heart, and pancreas, and detected
at low amounts in prostate and skeletal muscle in all of the four
Northern blot analysis. The significance of the results will be
discussed in the discussion section.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of
2 -2 in normal human
tissues. Human multiple tissue blots
(CLONTECH) were hybridized with
32P-labeled cDNA synthesized from the entire coding
sequence of 2 -2 (A and B).
Sizes of the RNA markers are indicated on the left. PBL, peripheral
blood lymphocyte. Probes for C, D, and
E are indicated at the bottom of each
figure.
|
|
Biochemical Properties of the 2 -2
Protein--
To characterize the biochemical properties of
2 -2 protein, we translated the 2 -2
cDNA in vitro and in vivo. The product of
in vitro translation is a single band with the molecular
mass of ~130 kDa (Fig. 2A),
which is consistent with the calculated molecular mass of 129,268 Daltons. For in vivo expression, the 2 -2
coding sequence was inserted into the mammalian expression vector
pcDNA3.1 (Invitrogen) and transfected into non-small cell lung
cancer cell line NCI-H1299, which does not express
2 -2 mRNA or its protein (Fig. 2C). An
affinity-purified anti- 2 -2 peptide antibody detected
an ~150-kDa protein in the lysate from 2 -2-transfected cells but not in cells transfected
with the vector control (Fig. 2B). Most likely, the increase
in the apparent molecular mass (129 to 150 kDa) compared with the
conceptually translated protein is the result of
N'-glycosylation, in agreement with multiple putative
N-glycosylation sites in the 2 -2 sequence, which represent known properties of the 2 -1 protein
(35). Endogenous 2 -2 protein of 150 kDa was also
detected in some lung tumor cell lines using the same antibody (Fig.
2C), which further confirmed our conceptual translation and
anti-peptide antibody preparation were correct.

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 2.
A, in vitro transcription and
translation of 2 -2. Lane 1, in
vitro transcription and translation of 2 -2 in
expression vector pcDNA3.1. Lane 2, no DNA was added in
the same reaction. The arrow indicates the expected 130 kDa
product. B, Western blot analysis of transfection of
NCI-H1299 cells with 2 -2. Lane 1,
transfection of NCI-H1299 cells with 2 -2 in
expression vector pcDNA3.1. Lane 2, transfection of
NCI-H1299 cells with pcDNA3.1 vector alone. Affinity-purified
anti- 2 -2 peptide antibody was used to detect the
protein product. The arrow indicates the expected protein
product. Sizes of the prestained protein molecular weight markers are
indicated on the right. C, 40 µg of protein from tumor
cell lysates were loaded in each lane. Lane 1,
NCI-H2O77 (adenocarcinoma); lane 2, NCI-H358
(adenocarcinoma); lane 3, NCI-H2106 (large cell
neuroendocrine carcinoma); lane 4, NCI-H1299 (large cell
carcinoma) cells.
|
|
Functional Properties of 2 -2--
To test for
functional expression of the 2 -2 subunit, we
performed a series of two-electrode voltage clamp experiments using the
Xenopus oocyte heterologous expression system. Injection of oocytes with cRNA encoding the pore-forming human 1B subunit together with an auxiliary 3 subunit resulted in
expression of functional N-type calcium channels in oocyte plasma
membranes with a peak current of 1.0 ± 0.1 µA
(n = 4) (Fig.
3A). Channel activity was
indicated as representative inward barium currents observed in response
to 0 mV and +20 mV test potentials. The magnitude of N-type currents
was increased 9-fold to 9.1 ± 1.4 µA (n = 10) when 1B and 3 were coexpressed with the rabbit
skeletal muscle 2 -1 subunit (Fig. 3B).
When co-expressed with 1B and 3 subunits, the
2 -2 subunit exerted a similar effect on N-type
channel expression, increasing peak current size to 7.6 ± 0.6 µA (n = 10) (Fig. 3C). No channel activity
was observed after injection of 2 -2 cRNA alone (data
not shown). By varying the test potential in the range from 100 mV to + 100 mV we established that the shape and position of current-voltage
relationships was similar for all three subunit combinations, with the
maximum current at 0 mV test potential and reversal potential at + 50 mV (Fig. 3D).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3.
Representative records of barium currents
evoked by step depolarization from 120 to 0 mV and +20 mV.
Oocytes were injected with cRNA encoding: A,
1B+ 3; B, 1B+ 3+ 2 -1;
C, 1B+ 3+ 2 -2. Residual capacitance
transients at the end of test pulses were removed. D, mean
current-voltage curves from two independent injections (mean ± S.E.) with 1B+ 3 (open circles), 1B+ 3+ 2 -1
(filled triangles), and 1B+ 3+ 2 -2 (filled
circles) cRNA combinations. E, current-voltage
relationships of 1C alone (filled circles) and
1C/ 2 -2 (circles) induced currents. Currents were
evoked by a series of test pulses of 50 mV to +70 mV from a holding
potential of 70 mV in 40 mM Ba2+ solution.
Average 1C currents were collected from 33 oocytes; 1C/ 2 -2
currents were from 31 oocytes isolated from three different frogs. Data
represent the mean ± S.E. F, current-voltage
relationships of 1G (filled squares)- and 1G/ 2 -2
(squares)-induced currents. Currents were elicited by test
pulses of 70 mV to +50 mV from a holding potential of 90 mV in 10 mM Ba2+ solution. Average 1G currents were
collected from 33 oocytes; 1G/ 2 -2 currents were from 32 oocytes isolated from four frogs. G, average stimulation of
1C and 1G currents by coexpression with 2 -2. Since
expression of the cloned T-type channels is highly variable between
batches of oocytes, each batch was injected with both 1 and
1 2 -2 and stimulation by 2 -2 was measured for each batch
then averaged.
|
|
Stimulation of N-type current expression by 2 -1 and
2 -2 subunits (Fig. 3, A-C) is similar to
the previously described effect of 2 -1 on P/Q-type
Ca2+ channels formed by 1A and subunits (36, 37),
which has been shown to depend on 2 -1 subunit glycosylation (35).
Thus, it is likely that 2 -2 subunit is glycosylated
when expressed in Xenopus oocytes, as is expected from
biochemical and sequence analysis. Noticeably, the
2 -1 but not the 2 -2 subunit was able to hasten N-type Ca2+ channel inactivation. Indeed, at
the end of a 50-ms test pulse to +20 mV, the size of the current was
reduced to 33 ± 10% (n = 8) of the peak current
for 1B+ 3+ 2 -1, to 59 ± 5%
(n = 24) of the peak current for
1B+ 3+ 2 -2, and to 51 ± 4%
(n = 15) of the peak current for 1B+ 3
subunit combinations.
To test for an 2 -2 effect on L-type channels, either
1C cRNA alone or 1C plus 2 -2 cRNA were injected
into oocytes. Peak currents measured during a series of test potentials
were averaged (Fig. 3E). When peak current amplitudes
measured at +30 mV were compared, 1C/ 2 -2 currents
were significantly larger than 1C by 201% (t test,
p < 0.001). However, there were no significant differences in the position of the current-voltage curves, which peaked
at ~+35 mV. Similar to the 2 -2 effect on 1C
channels, coinjection of 2 -2 cRNA with 1G cRNA
increased T-type current amplitudes by 176% (t test,
p < 0.05), compared with 1G alone (Fig.
3F). There were no significant differences in their
biophysical properties including activation threshold, position of
their current-voltage curves, reversal potentials, and activation and
inactivation kinetics. We conclude from these experiments that the
cloned 2 -2 protein is able to function as an
auxiliary subunit of all three subfamilies of voltage-gated
Ca2+ channels.
 |
DISCUSSION |
This study describes the cloning and functional properties of a
novel 2 subunit of voltage-gated Ca2+
channels. The gene (CACNA2D2) was discovered by positional
cloning while searching for a lung cancer tumor suppressor gene.
GenBankTM deposits AF040709 and AF042792 represent alternatively
spliced forms (in the 5'-untranslated region) with the same conceptual 1,145-amino acid sequence. GenBankTM deposit AF042793 represents another 5' alternatively spliced form uncommonly found in lung cDNA
clones resulting in an open reading frame beginning at the second 5'
methionine at codon 70 and, thus, resulting in a deletion of the 70 N-terminal amino acids found in the common 2 -2 form studied here. Sequences were deposited in the GenBankTM to stimulate research on its function. Klugbauer et al. (7) cloned
another related 2 subunit, then proposed the
following nomenclature: 2 -1, for the original
2 cloned from skeletal muscle; 2 -2, for the protein described herein, and 2 -3, for their
novel sequence. Similarly the genes will be referred to as
CACNA2D1, CACNA2D2, and CACNA2D3,
respectively (38). While this paper was in preparation, an
2 -2 clone (KIAA0558, GenBankTM number AB011130) was
independently isolated by the Kazusa DNA Research Institute from human
brain as part of large scale anonymous cDNA sequencing efforts
(39). The present study reports on the expression of the
CACNA2D2 gene in human tissues and on electrophysiological
studies that show it can modulate the expression of functional
Ca2+ channels.
Expression of the CACNA2D2 gene was determined by Northern
analysis. It was most highly expressed in lung and testis, well expressed in brain, heart, and pancreas, and expressed to a lower extent in skeletal muscle and prostate. Our results do not agree with
those of Klugbauer et al. (7), who found abundant
cross-reactive material from what they reported to be
2 -2 in mRNA from skeletal muscle, pancreas, and
heart, with hardly any signal from lung. We feel our expression pattern
is the correct one since we had performed four independent Northern
blot analysis using four probes including one (nt 2729-3293) that is
very similar to the probe that Klugbauer et al. (7) used
(nucleotides 2877-3249).The result of our cDNA screening also
supports the high expression of 2 -2 in lung, since we
obtained 120 2 -2 clones from a screening of 1 million
clones of a lung cDNA library. A possible explanation for the
discrepancy could be that their probe cross-reacted with 2 -1, since it has an expression pattern very similar
to what they reported for 2 -2 (40). Furthermore, it
is unlikely that 2 -2 is highly expressed in skeletal
muscle, because 2 proteins were purified from that
tissue, and only the sequence of 2 -1 was detected
(13).
The tissue distribution of mRNA for the three 2
subunits is very different (7, 40). All three genes are expressed in brain, which is the only tissue that expresses 2 -3.
The 2 -1 gene is highly expressed in skeletal muscle,
where we find little or no expression of 2 -2. Both
2 -1 and -2 are expressed in heart. The
2 -2 gene is highly expressed in lung where the
expression of 2 -1 is low. It will be important to
determine what cells in the lung express 2 -2;
however, we have shown that several lung cancers representing different
lung epithelial types can express 2 -2, so that
presumably some normal lung epithelial cells also express
2 -2. In this regard, it is also interesting to note
that 1C was cloned from lung cDNA libraries (19), and L-type
currents have been characterized from tracheal smooth muscle (41). The
only subunit detected in lung mRNA is 2 (3). Therefore, the minimum subunit composition of lung L-type channels can
be deduced as 1C 2 -2 2.
The possible role of 2 -2 as a Ca2+
channel subunit was examined using the Xenopus oocyte
expression system. We tested for an effect on currents using three 1
subunits. The 1 subunits were chosen to represent each of the three
subfamilies of Ca2+ channels: Cav1.2 or 1C,
Cav2.2 or 1B, and a low voltage-activated channel
Cav3.1 or 1G. In each case, 2 -2 was
able to stimulate functional expression. No effect was observed on the
biophysical properties of the current, suggesting that
2 -2 simply increased the number of functional
channels at the plasma membrane. Similar results were obtained with
2 -1 on the expression of 1G in both COS cells and
Xenopus oocytes (4).
Coexpression studies of 2 -2 plus 1B also included
the 3 subunit. In these experiments we observed the
largest stimulatory effect on expression. Some studies report a
synergistic action of 2 and on 1B expression
(17). The experiments with 1C did not include a subunit because
they stimulate current so much already that it has been difficult to
see any effect of 2 at the whole cell level (18).
Interest in the physiological roles of Ca2+ channels has
increased due to findings that mutations in their genes can lead to human diseases (42). In addition, defects in the auxiliary subunits of
Ca2+ channels have been described in mouse models of
absence epilepsy. These include mouse strains that have lost the
expression of 4 and the recently discovered
2 subunit (5, 43). In this regard, after we cloned
CACNA2D2 we noted with great interest that the syntenic
region in the mouse (mouse chromosome 9, 59.0-60.0 centimorgan) contains the mouse mutant ducky and also 4 other flanking
genes (CISH, GNAI2, GNAT, and HYAL1)
that we have identified in our ~600-kb region (25) and deposited as
GenBankTM numbers AF132297 for CISH and U03056 for
HYAL1. Our partial mouse cDNA sequence is 92% identical
to the human 2 -2 sequence (GenBankTM number AF169633.1). In fact,
preliminary evidence suggests that loss of 2 -2 expression leads
to the epileptic phenotype, ducky (44). Histological
examination of mouse ducky mutants reveals atrophy of the
cerebellum, medulla oblongata, and spinal cord (45). These mice develop
a spike-and-wave phenotype in the electroencephalogram, which is
similar to that observed in absence epilepsy patients. Thus, it will be
of great interest to see if inherited defects in CACNA2D2
also occur in humans (46). It remains to be determined how these
Ca2+ channel defects lead to these epileptic phenotypes.
We began these studies searching for a human lung cancer tumor
suppressor gene. The specific 600-kb 3p21.3 chromosome region within
which the CACNA2D2 gene resides is a site of homozygous deletions occurring in lung and breast cancer and is a frequent target
region for allele loss occurring very early in the pathogenesis of lung
and other cancers (25, 47-49). Thus, we are also studying CACNA2D2 for mutations, expression alterations, and
functional characteristics of a tumor suppressor gene in these cancers.
In this regard we were interested to see its high expression in normal lung tissue and in some but not all lung cancer cell lines. A clinical
connection between voltage-dependent calcium channels and
lung cancer is well established by the Lambert-Eaton myasthenic syndrome, seen in some small cell lung cancer patients (50). Lambert-Eaton myasthenic syndrome is a human autoimmune disorder that
impairs neuromuscular transmission such that patients with this
syndrome have a defect in the Ca2+-dependent
quantal release of acetylcholine from motor nerve terminals (51). In
this syndrome patients develop antibodies (presumably initiated by
expression of the channel proteins in their small cell lung cancer)
that react with voltage-gated calcium channel polypeptides that block
depolarization-induced Ca2+ influx, leading to the
myasthenia (52-54). In this report we have seen 2 -2
to functionally interact with the T-type channel subunit 1G. Thus,
it was of great interest to us when Toyota et al. (55) reported that CACNA1G encoding this subunit could have its
expression inactivated by aberrant methylation of its 5' CpG island in
human tumors such as colorectal cancers, gastric cancers, and acute myelogenous leukemias. CACNA1G maps to chromosome region
17q21, another site of frequent allele loss in human cancer. Such
acquired CpG island methylation in promoter regions of cancer cells as an acquired abnormality silencing genes such as tumor suppressor genes
is well described (56, 57). Ca2+ influx via voltage-gated
calcium channels including T-type channels and intracellular calcium
signaling plays a role in apoptosis (58). In addition, platelet-derived
growth factor-stimulated calcium influx changed during transformation
of mouse C3H 10T1/2 fibroblasts accompanied by a marked reduction in
expression of T-type calcium channels (59). Thus, the inactivation of
voltage-gated calcium channel subunits such as CACNA2D2 and
CACNA1G by any of several means merit serious consideration
as an important step in cancer pathogenesis.
 |
ACKNOWLEDGEMENTS |
We thank Meena Viswanathan, Yang Song, and
David Burbee for assistance in this research.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
(NCI) Grants CA71618, P50-CA70907, NS38691, and NO1-CO-56000 and by the
Hibino Memorial Medical Fund.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.

To whom correspondence should be addressed: Hamon Center for
Therapeutic Oncology Research, University of Texas Southwestern Medical
Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8593. Tel.:
214-648-4900; Fax: 214-648-4940; E-mail:
minna@simmons.swmed.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
contig, group of
overlapping clones;
kb, kilobase(s).
 |
REFERENCES |
| 1.
|
Perez-Reyes, E.,
and Schneider, T.
(1995)
Kidney Int.
48,
1111-1124[Medline]
[Order article via Infotrieve]
|
| 2.
|
Randall, A.,
and Benham, C.
(1999)
Mol. Cell. Neurosci.
14,
255-272[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Castellano, A.,
and Perez-Reyes, E.
(1994)
Biochem. Soc. Trans.
22,
483-488[Medline]
[Order article via Infotrieve]
|
| 4.
|
Dolphin, A. C.,
Wyatt, C. N.,
Richards, J.,
Beattie, R. E.,
Craig, P.,
Lee, J.-H.,
Cribbs, L. L.,
Volsen, S. G.,
and Perez-Reyes, E.
(1999)
J. Physiol. (Lond)
519,
35-45[Abstract/Free Full Text]
|
| 5.
|
Letts, V. A.,
Felix, R.,
Biddlecome, G. H.,
Arikkath, J.,
Mahaffey, C. L.,
Valenzuela, A.,
Bartlett II, F. S.,
Mori, Y.,
Campbell, K. P.,
and Frankel, W. N.
(1998)
Nat. Genet.
19,
340-347[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Black, J. L., III,
and Lennon, V. A.
(1999)
Mayo Clin. Proc.
74,
357-61[Abstract]
|
| 7.
|
Klugbauer, N.,
Lacinova, L.,
Marais, E.,
Hobom, M.,
and Hofmann, F.
(1999)
J. Neurosci.
19,
684-691[Abstract/Free Full Text]
|
| 8.
|
Sharp, A. H.,
and Campbell, K. P.
(1989)
J. Biol. Chem.
264,
2816-2825[Abstract/Free Full Text]
|
| 9.
|
Suh-Kim, H.,
Wei, X.,
Klos, A.,
Pan, S.,
Ruth, P.,
Flockerzi, V.,
Hofmann, F.,
Perez-Reyes, E.,
and Birnbaumer, L.
(1996)
Receptors & Channels
4,
217-225[Medline]
[Order article via Infotrieve]
|
| 10.
|
Singer, D.,
Biel, M.,
Lotan, I.,
Flockerzi, V.,
Hofmann, F.,
and Dascal, N.
(1991)
Science
253,
1553-1557[Abstract/Free Full Text]
|
| 11.
|
Schmid, A.,
Barhanin, J.,
Coppola, T.,
Borsotto, M.,
and Lazdunski, M.
(1986)
Biochemistry
25,
3492-3495[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
McEnery, M. W.,
Snowman, A. M.,
Sharp, A. H.,
Adams, M. E.,
and Snyder, S. H.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
11095-11099[Abstract/Free Full Text]
|
| 13.
|
Ellis, S. B.,
Williams, M. E.,
Ways, N. R.,
Brenner, R.,
Sharp, A. H.,
Leung, A. T.,
Campbell, K. P.,
McKenna, E.,
Koch, W. J.,
Hui, A.,
et al..
(1988)
Science
241,
1661-1664[Abstract/Free Full Text]
|
| 14.
|
De Jongh, K. S.,
Warner, C.,
and Catterall, W. A.
(1990)
J. Biol. Chem.
265,
14738-14741[Abstract/Free Full Text]
|
| 15.
|
Williams, M. E.,
Feldman, D. H.,
McCue, A. F.,
Brenner, R.,
Velicelebi, G.,
Ellis, S. B.,
and Harpold, M. M.
(1992)
Neuron
8,
71-84[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Brown, J. P.,
and Gee, N. S.
(1998)
J. Biol. Chem.
273,
25458-25465[Abstract/Free Full Text]
|
| 17.
|
Brust, P. F.,
Simerson, S.,
Mccue, A. F.,
Deal, C. R.,
Schoonmaker, S.,
Williams, M. E.,
Velicelebi, G.,
Johnson, E. C.,
Harpold, M. M.,
and Ellis, S. B.
(1993)
Neuropharmacology
32,
1089-1102[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Wei, X.,
Pan, S.,
Lang, W.,
Kim, H.,
Schneider, T.,
Perez-Reyes, E.,
and Birnbaumer, L.
(1995)
J. Biol. Chem.
270,
27106-27111[Abstract/Free Full Text]
|
| 19.
|
Biel, M.,
Ruth, P.,
Bosse, E.,
Hullin, R.,
Stuhmer, W.,
Flockerzi, V.,
and Hofmann, F.
(1990)
FEBS Lett.
269,
409-412[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Shirokov, R.,
Ferreira, G.,
Yi, J.,
and Rios, E.
(1998)
J. Gen. Physiol.
111,
807-823[Abstract/Free Full Text]
|
| 21.
|
Bangalore, R.,
Mehrke, G.,
Gingrich, K.,
Hofmann, F.,
and Kass, R. S.
(1996)
Am. J. Physiol.
270,
H1521-H1528[Abstract/Free Full Text]
|
| 22.
|
Jones, L. P.,
Wei, S. K.,
and Yue, D. T.
(1998)
J. Gen. Physiol.
112,
125-143[Abstract/Free Full Text]
|
| 23.
|
Qin, N.,
Olcese, R.,
Stefani, E.,
and Birnbaumer, L.
(1998)
Am. J. Physiol.
274,
C1324-C1331[Abstract/Free Full Text]
|
| 24.
|
Stefani, A.,
Spadoni, F.,
and Bernardi, G.
(1998)
Neuropharmacology
37,
83-91[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Wei, M. H.,
Latif, F.,
Bader, S.,
Kashuba, V.,
Chen, J. Y.,
Duh, F. M.,
Sekido, Y.,
Lee, C. C.,
Geil, L.,
Kuzmin, I.,
Zabarovsky, E.,
Klein, G.,
Zbar, B.,
Minna, J. D.,
and Lerman, M. I.
(1996)
Cancer Res.
56,
1487-1492[Abstract/Free Full Text]
|
| 26.
|
Fondon, J. W., III,
Mele, G. M.,
Brezinschek, R. I.,
Cummings, D.,
Pande, A.,
Wren, J.,
O'Brien, K. M.,
Kupfer, K. C.,
Wei, M. H.,
Lerman, M.,
Minna, J. D.,
and Garner, H. R.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7514-7519[Abstract/Free Full Text]
|
| 27.
|
Ellinor, P. T.,
Zhang, J. F.,
Horne, W. A.,
and Tsien, R. W.
(1994)
Nature
372,
272-275[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Tanabe, T.,
Takeshima, H.,
Mikami, A.,
Flockerzi, V.,
Takahashi, H.,
Kangawa, K.,
Kojima, M.,
Matsuo, H.,
Hirose, T.,
and Numa, S.
(1987)
Nature
328,
313-318[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Hullin, R.,
Singer-Lahat, D.,
Freichel, M.,
Biel, M.,
Dascal, N.,
Hofmann, F.,
and Flockerzi, V.
(1992)
EMBO J.
11,
885-890[Medline]
[Order article via Infotrieve]
|
| 30.
|
Rudy, B.,
and Iverson, L. E.
(1992)
in
Methods in Enzymology
(Abelson, J. N.
, and Simon, M. I., eds), Vol. 207
, pp. 225-390, Academic Press, Inc., San Diego
|
| 31.
|
Bezprozvanny, I.,
Scheller, R. H.,
and Tsien, R. W.
(1995)
Nature
378,
623-626[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Wei, X.,
Neely, A.,
Olcese, R.,
Lang, W.,
Stefani, E.,
and Birnbaumer, L.
(1996)
Receptors & Channels
4,
205-215[Medline]
[Order article via Infotrieve]
|
| 33.
|
Perez-Reyes, E.,
Cribbs, L. L.,
Daud, A.,
Lacerda, A. E.,
Barclay, J.,
Williamson, M. P.,
Fox, M.,
Rees, M.,
and Lee, J.-H.
(1998)
Nature
391,
896-900[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Chuang, R. S.-I.,
Jaffe, H.,
Cribbs, L. L.,
Perez-Reyes, E.,
and Swartz, K. J.
(1998)
Nat. Neurosci.
1,
668-674[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Gurnett, C. A.,
De Waard, M.,
and Campbell, K. P.
(1996)
Neuron
16,
431-440[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
De Waard, M.,
and Campbell, K. P.
(1995)
J. Physiol. (Lond.)
485,
619-634[Abstract/Free Full Text]
|
| 37.
|
Walker, D.,
and De Waard, M.
(1998)
Trends Neurosci.
21,
148-154[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Lory, P.,
Ophoff, R. A.,
and Nahmias, J.
(1997)
Hum. Genet.
100,
149-150[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Nagase, T.,
Ishikawa, K.,
Miyajima, N.,
Tanaka, A.,
Kotani, H.,
Nomura, N.,
and Ohara, O.
(1998)
DNA Res.
5,
31-39[Abstract]
|
| 40.
|
Angelotti, T.,
and Hofmann, F.
(1996)
FEBS Lett.
397,
331-337[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Welling, A.,
Felbel, J.,
Peper, K.,
and Hofmann, F.
(1992)
Am. J. Physiol.
262,
L351-L359[Abstract/Free Full Text]
|
| 42.
|
Lehmann-Horn, F.,
and Jurkat-Rott, K.
(1999)
Physiol. Rev.
79,
1317-1372[Abstract/Free Full Text]
|
| 43.
|
Burgess, D. L.,
Jones, J. M.,
Meisler, M. H.,
and Noebels, J. L.
(1997)
Cell
88,
385-392[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Barclay, J.,
Kusumi, K.,
Lander, E.,
Perez-Reyes, E.,
Frankel, W.,
Gardiner, M.,
and Rees, M.
(1999)
Epilepsia
40,
137
|
| 45.
|
Meier, H.
(1968)
Acta Neuropathol.
11,
15-28[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Noebels, J. L.
(1994)
in
Idiopathic Generalized Epilepsies: Clinical, Experimental, and Genetic Aspects
(Malafosse, A.
, Genton, P.
, Hirsch, E.
, Marescaux, D.
, Broglin, D.
, and Bernasconi, R., eds)
, pp. 215-225, John Libbey & Co. Ltd., London
|
| 47.
|
Sekido, Y.,
Ahmadian, M.,
Wistuba, II,
Latif, F.,
Bader, S.,
Wei, M. H.,
Duh, F. M.,
Gazdar, A. F.,
Lerman, M. I.,
and Minna, J. D.
(1998)
Oncogene
16,
3151-3157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Sekido, Y.,
Fong, K.,
and Minna, J.
(1998)
Biochim. Biophys. Acta
1378,
F21-F59[Medline]
[Order article via Infotrieve]
|
| 49.
|
Wistuba, I.,
Behrens, C.,
Milchgrub, S.,
Bryant, D.,
Hung, J.,
Minna, J. D.,
and Gazdar, A. F.
(1999)
Oncogene
18,
643-650[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Takamori, M.
(1999)
Intern. Med.
38,
86-96[Medline]
[Order article via Infotrieve]
|
| 51.
|
O'Neill, J. H.,
Murray, N. M.,
and Newsom-Davis, J.
(1988)
Brain
111,
577-596[Abstract/Free Full Text]
|
| 52.
|
Lennon, V. A.,
Kryzer, T. J.,
Griesmann, G. E.,
O'Suilleabhain, P. E.,
Windebank, A. J.,
Woppmann, A.,
Miljanich, G. P.,
and Lambert, E. H.
(1995)
N. Engl. J. Med.
332,
1467-1474[Abstract/Free Full Text]
|
| 53.
|
Raymond, C.,
Walker, D.,
Bichet, D.,
Iborra, C.,
Martin-Moutot, N.,
Seagar, M.,
and De Waard, M.
(1999)
Neuroscience
90,
269-277[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Voltz, R.,
Carpentier, A. F.,
Rosenfeld, M. R.,
Posner, J. B.,
and Dalmau, J.
(1999)
Muscle Nerve
22,
119-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Toyota, M.,
Ho, C.,
Ohe-Toyota, M.,
Baylin, S. B.,
and Issa, J. P.
(1999)
Cancer Res.
59,
4535-4541[Abstract/Free Full Text]
|
| 56.
|
Baylin, S. B.,
Herman, J. G.,
Graff, J. R.,
Vertino, P. M.,
and Issa, J. P.
(1998)
Adv. Cancer Res.
72,
141-196[Medline]
[Order article via Infotrieve]
|
| 57.
|
Schmutte, C.,
and Jones, P. A.
(1998)
Biol. Chem. Hoppe-Seyler
379,
377-88
|
| 58.
|
Berridge, M. J.,
Bootman, M. D.,
and Lipp, P.
(1998)
Nature
395,
645-648[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Estacion, M.,
and Mordan, L. J.
(1997)
Cell. Signal.
9,
363-366[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. V. Ly, C.-K. Yao, P. Verstreken, T. Ohyama, and H. J. Bellen
straightjacket is required for the synaptic stabilization of cacophony, a voltage-gated calcium channel {alpha}1 subunit
J. Cell Biol.,
April 3, 2008;
181(1):
157 - 170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Vela, M. I. Perez-Millan, D. Becu-Villalobos, and G. Diaz-Torga
Different kinases regulate activation of voltage-dependent calcium channels by depolarization in GH3 cells
Am J Physiol Cell Physiol,
September 1, 2007;
293(3):
C951 - C959.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Gaborit, S. Le Bouter, V. Szuts, A. Varro, D. Escande, S. Nattel, and S. Demolombe
Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart
J. Physiol.,
July 15, 2007;
582(2):
675 - 693.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Tuluc, G. Kern, G. J. Obermair, and B. E. Flucher
Computer modeling of siRNA knockdown effects indicates an essential role of the Ca2+ channel {alpha}2{delta}-1 subunit in cardiac excitation-contraction coupling
PNAS,
June 26, 2007;
104(26):
11091 - 11096.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Gazulla, I. Benavente, and M. Sarasa
New Therapies for Ataxia-Telangiectasia
Arch Neurol,
April 1, 2007;
64(4):
607 - 608.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-N. Yang and P.-O. Berggren
The Role of Voltage-Gated Calcium Channels in Pancreatic {beta}-Cell Physiology and Pathophysiology
Endocr. Rev.,
October 1, 2006;
27(6):
621 - 676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-N. Yang and P.-O. Berggren
{beta}-Cell CaV channel regulation in physiology and pathophysiology
Am J Physiol Endocrinol Metab,
January 1, 2005;
288(1):
E16 - E28.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Marionneau, B. Couette, J. Liu, H. Li, M. E. Mangoni, J. Nargeot, M. Lei, D. Escande, and S. Demolombe
Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart
J. Physiol.,
January 1, 2005;
562(1):
223 - 234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. V. Ivanov, J. M. Ward, L. Tessarollo, D. McAreavey, V. Sachdev, L. Fananapazir, M. K. Banks, N. Morris, D. Djurickovic, D. E. Devor-Henneman, et al.
Cerebellar Ataxia, Seizures, Premature Death, and Cardiac Abnormalities in Mice with Targeted Disruption of the Cacna2d2 Gene
Am. J. Pathol.,
September 1, 2004;
165(3):
1007 - 1018.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Dubel, C. Altier, S. Chaumont, P. Lory, E. Bourinet, and J. Nargeot
Plasma Membrane Expression of T-type Calcium Channel {alpha}1 Subunits Is Modulated by High Voltage-activated Auxiliary Subunits
J. Biol. Chem.,
July 9, 2004;
279(28):
29263 - 29269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yasuda, R. J. Lewis, and D. J. Adams
Overexpressed Cav{beta}3 Inhibits N-type (Cav2.2) Calcium Channel Currents through a Hyperpolarizing Shift of "Ultra-slow" and "Closed-state" Inactivation
J. Gen. Physiol.,
March 29, 2004;
123(4):
401 - 416.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Tada, M. Ohmori, and H. Iida
Molecular Dissection of the Hydrophobic Segments H3 and H4 of the Yeast Ca2+ Channel Component Mid1
J. Biol. Chem.,
March 7, 2003;
278(11):
9647 - 9654.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Perez-Reyes
Molecular Physiology of Low-Voltage-Activated T-type Calcium Channels
Physiol Rev,
January 1, 2003;
83(1):
117 - 161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Qin, S. Yagel, M.-L. Momplaisir, E. E. Codd, and M. R. D'Andrea
Molecular Cloning and Characterization of the Human Voltage-Gated Calcium Channel alpha 2delta -4 Subunit
Mol. Pharmacol.,
September 1, 2002;
62(3):
485 - 496.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Tomizawa, T. Kohno, H. Kondo, A. Otsuka, M. Nishioka, T. Niki, T. Yamada, A. Maeshima, K. Yoshimura, R. Saito, et al.
Clinicopathological Significance of Epigenetic Inactivation of RASSF1A at 3p21.3 in Stage I Lung Adenocarcinoma
Clin. Cancer Res.,
July 1, 2002;
8(7):
2362 - 2368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Barclay, N. Balaguero, M. Mione, S. L. Ackerman, V. A. Letts, J. Brodbeck, C. Canti, A. Meir, K. M. Page, K. Kusumi, et al.
Ducky Mouse Phenotype of Epilepsy and Ataxia Is Associated with Mutations in the Cacna2d2 Gene and Decreased Calcium Channel Current in Cerebellar Purkinje Cells
J. Neurosci.,
August 15, 2001;
21(16):
6095 - 6104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Burbee, E. Forgacs, S. Zochbauer-Muller, L. Shivakumar, K. Fong, B. Gao, D. Randle, M. Kondo, A. Virmani, S. Bader, et al.
Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression
J Natl Cancer Inst,
May 2, 2001;
93(9):
691 - 699.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Marais, N. Klugbauer, and F. Hofmann
Calcium Channel alpha 2delta Subunits---Structure and Gabapentin Binding
Mol. Pharmacol.,
April 16, 2001;
59(5):
1243 - 1248.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Jen and D. H. Geschwind
Ataxia and Calcium Channels: What a Headache!
Arch Neurol,
February 1, 2001;
58(2):
179 - 180.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. I. Lerman and J. D. Minna
The 630-kb Lung Cancer Homozygous Deletion Region on Human Chromosome 3p21.3: Identification and Evaluation of the Resident Candidate Tumor Suppressor Genes
Cancer Res.,
November 1, 2000;
60(21):
6116 - 6133.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Hering, S. Berjukow, S. Sokolov, R. Marksteiner, R. G Weiss, R. Kraus, and E. N Timin
Molecular determinants of inactivation in voltage-gated Ca2+ channels
J. Physiol.,
October 15, 2000;
528(2):
237 - 249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Felix
Channelopathies: ion channel defects linked to heritable clinical disorders
J. Med. Genet.,
October 1, 2000;
37(10):
729 - 740.
[Abstract]
[Full Text]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|